Avacopan as an additional therapeutic intervention to promote renal recovery in severe ANCA-associated vasculitis: A case report

Aleks D Atrens; Holly Hutton; Eoin O'Sullivan; John Moore; Krishan Madhan

doi:10.1111/nep.14253

Avacopan as an additional therapeutic intervention to promote renal recovery in severe ANCA-associated vasculitis: A case report

Nephrology (Carlton). 2024 Feb;29(2):105-107. doi: 10.1111/nep.14253. Epub 2023 Nov 20.

Authors

Aleks D Atrens¹, Holly Hutton², Eoin O'Sullivan^{3

4}, John Moore¹, Krishan Madhan¹

Affiliations

¹ Department of Renal Medicine, Hervey Bay Hospital, Hervey Bay, Queensland, Australia.
² Department of Renal Medicine, Alfred Health, Melbourne, Victoria, Australia.
³ Kidney Health Service, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia.
⁴ Institute for Molecular Bioscience, University of Queensland, Brisbane, Queensland, Australia.

PMID: 37985226
DOI: 10.1111/nep.14253

Abstract

Avacopan, a C5a receptor antagonist (C5aR) presents a new therapeutic option to improve outcomes in ANCA-associated vasculitis (AAV). Here we present a case report of a patient initially requiring kidney replacement therapy (KRT), where avacopan was added as an additional adjunctive therapeutic agent late in the treatment course.

Keywords: ANCA Associated Vasculitis (AAV); acute kidney failure; anti-neutrophil cytoplasmic antibodies (ANCA); avacopan; granulomatosis with polyangiitis (GPA).

Publication types

Case Reports

MeSH terms

Aniline Compounds / therapeutic use
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis* / complications
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis* / diagnosis
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis* / drug therapy
Antibodies, Antineutrophil Cytoplasmic
Granulomatosis with Polyangiitis* / drug therapy
Humans
Kidney
Nipecotic Acids*

Substances

avacopan
Aniline Compounds
Antibodies, Antineutrophil Cytoplasmic
Nipecotic Acids